Clinical Trial Update: Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Cefiderocol (S-649266) versus best available therapy for severe infections due to carbapenem-resistant Gram-negative pathogens; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bloodstream Infections
• Complicated Urinary Tract Infection
• Healthcare-associated Pneumonia
• Hospital-acquired Pneumonia
• Sepsis
• Ventilator-associated Pneumonia

Drugs mentioned

• Cefiderocol (cefiderocol)

Snippet

Sponsor: Shionogi | Conditions: Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI) | Phase 3 | Status: COMPLETED | Results posted: 2020-12-17